Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Table 4 Individual target tophus response categories at patient’s final visit in the randomized trials ^a

Categories	Pegloticase	Pegloticase	Placebo
	biweekly	monthly
	(n= 62)	(n= 64)	(n= 29)
Total number of tophi^b	229	201	117
Response category, n (%)
CR	57 (25)	30 (15)	2 (2)
PR or MR	49 (21)	33 (16)	12 (10)
SD	111 (49)	121 (60)	89 (76)
PD	1 (0.4)	1 (0.5)	3 (3)
Unable to evaluate	11 (5)	16 (8)	11 (9)

^aCR, complete response; MR, marked response; PD: progressive disease; PR, partial response; SD: stable disease. ^bTotal tophi includes both measurable and unmeasurable tophi.

ISSN: 1478-6362